Trends in the treatment of cutaneous T-cell lymphoma – critical evaluation and perspectives on vorinostat

References

• Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116(5):767–771.
   PubMed Web of Science ®Google Scholar
• Duvic M, Foss FM. Mycosis fungoides: pathophysiology and emerging therapies. Semin Oncol. 2007;34(6 Suppl 5):S21–S28.
   Web of Science ®Google Scholar
• Olsen EA, Rook AH, Zic J, et al. Sezary syndrome: immunopathogen- esis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 2011;64(2):352–404.
   PubMed Web of Science ®Google Scholar
• Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol 2009;48(3):243–252.
   PubMed Web of Science ®Google Scholar
• Jackow CM, McHam JB, Friss A, Alvear J, Reveille JR, Duvic M. HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma. J Invest Dermatol 1996;107(3):373–376.
   Google Scholar
• Ni X, Zhang C, Talpur R, Duvic M. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol 2005;124(4):741–750.
   Web of Science ®Google Scholar
• Whittemore AS, Holly EA, Lee IM, et al. Mycosis fungoides in relation to environmental exposures and immune response: a case-control study. J Natl Cancer Inst. 1989;81(20):1560–1567.
   Google Scholar
• Mirvish ED, Pomerantz RG, Geskin LJ. Infectious agents in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2011;64(2):423–431.
   PubMed Web of Science ®Google Scholar
• Vega F, Luthra R, Medeiros LJ, et al. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood. 2002;100(9):3369–3373.
   Web of Science ®Google Scholar
• Berger CL, Hanlon D, Kanada D, et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood. 2002;99(8):2929–2939.
   Web of Science ®Google Scholar
• Kacinski BM, Flick M. Apoptosis and cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001;941:194–199.
   Web of Science ®Google Scholar
• Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115(4):798–812.
   PubMed Web of Science ®Google Scholar
• Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456–2471.
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (sub- eroylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–39.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410–5417.
   PubMed Web of Science ®Google Scholar
• Duvic M, Donato M, Dabaja B, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol. 2010;28(14):2365–2372.
   PubMed Web of Science ®Google Scholar
• Duvic M. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. Oncology (Williston Park). 2007;21(2 Suppl 1):33–40.
   Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109–3115.
   PubMed Web of Science ®Google Scholar
• Beumer JH, Tawbi H. Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol. 2010;5(3):196–208.
   Google Scholar
• Ellis L, Pili R. Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals (Basel). 2010;3(8):2411–2469.
   Google Scholar
• Lemoine M, Younes A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med. 2010;10(54):462–470.
   PubMed Web of Science ®Google Scholar
• Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology. 2008;53(3):267–277.
   PubMed Web of Science ®Google Scholar
• Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009;280(2):168–176.
   PubMed Web of Science ®Google Scholar
• Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2005;102(10):3697–3702.
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007;5(10):981–989.
   PubMed Web of Science ®Google Scholar
• Zain J, O’Connor OA. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest New Drugs. 2010;28 Suppl 1(1): S58–S78.
   Google Scholar
• Sambucetti LC, Fischer DD, Zabludoff S, et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem. 1999;274(49):34940–34947.
   Web of Science ®Google Scholar
• Sandor V Senderowicz A, Mertins S, et al. P21-dependent g(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer. 2000;83(6):817–825.
   PubMed Web of Science ®Google Scholar
• Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol. 2005;125(5):1045–1052.
   PubMed Web of Science ®Google Scholar
• Emanuele S, Lauricella M, Tesoriere G. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). Int J Oncol. 2008;33(4):637–646.
   PubMed Web of Science ®Google Scholar
• Nalabothula N, Carrier F. Cancer cells’ epigenetic composition and predisposition to histone deacetylase inhibitor sensitization. Epigenomics. 2011;3(2):145–155.
   Web of Science ®Google Scholar
• Ellis L, Bots M, Lindemann RK, et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood. 2009;114(2):380–393.
   PubMed Web of Science ®Google Scholar
• Shao W, Growney JD, Feng Y, et al. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance. Int J Cancer. 2010;127(9):2199–2208.
   PubMed Web of Science ®Google Scholar
• Droin N, Guery L, Benikhlef N, Solary E. Targeting apoptosis proteins in hematological malignancies. Cancer Lett. 2011;30:30.
   Google Scholar
• Inoue S, Mai A, Dyer MJ, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2006;66(13):6785–6792.
   PubMed Web of Science ®Google Scholar
• Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2004;101(52):18030–18035.
   PubMed Web of Science ®Google Scholar
• Robert T, Vanoli F, Chiolo I, et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature. 2011;471(7336):74–79.
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. Histone deacety- lase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer. 2002;97(3):290–296.
   Web of Science ®Google Scholar
• Qian DZ, Kato Y, Shabbeer S, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res. 2006;12(2):634–642.
   PubMed Web of Science ®Google Scholar
• Grabiec AM, Tak PP, Reedquist KA. Function of histone deacetylase inhibitors in inflammation. Crit Rev Immunol. 2011;31(3):233–263.
   PubMed Web of Science ®Google Scholar
• Duvic M, Vanaclocha F, Bernengo MG, et al. Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-cell Lymphoma (CTCL) (abstract). J Clin Oncol. 2008;26(May 20 Suppl):8555.
   Google Scholar
• Pohlman B, Advani R, Duvic M, et al. Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma (abstract). Blood. 2009;110:3453.
   Web of Science ®Google Scholar
• Kelly WK, Marks PA. Drug insight: Histone deacetylase inhibitors – development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol. 2005;2(3):150–157.
   PubMedGoogle Scholar
• Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010;6(3):238–243.
   PubMed Web of Science ®Google Scholar
• Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27(32):5459–5468.
   PubMed Web of Science ®Google Scholar
• Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A. 2001;98(19):10833–10838.
   PubMed Web of Science ®Google Scholar
• Lee JH, Choy ML, Ngo L, Foster SS, Marks PA. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci U S A. 2010;107(33):14639–14644.
   PubMed Web of Science ®Google Scholar
• Kelly WK, O’Connor OA, Krug LM, et al. Phase I study of an oral his- tone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23(17):3923–3931.
   PubMed Web of Science ®Google Scholar
• Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21 WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A. 2004;101(5):1241–1246.
   PubMed Web of Science ®Google Scholar
• Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11(9):621–632.
   PubMed Web of Science ®Google Scholar
• Qin JZ, Zhang CL, Kamarashev J, Dummer R, Burg G, Dobbeling U. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood. 2001;98(9):2778–2783.
   Web of Science ®Google Scholar
• Fantin VR, Loboda A, Paweletz CP, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 2008;68(10):3785–3794.
   PubMed Web of Science ®Google Scholar
• Tiffon C, Adams J, van der Fits L, et al. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J Pharmacol. 2011;162(7):1590–1602.
   Web of Science ®Google Scholar
• Cao Y. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv Cancer Res. 2008;100:113–131.
   PubMed Web of Science ®Google Scholar
• Fotheringham S, Epping MT, Stimson L, et al. Genome-wide loss- of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell. 2009;15(1):57–66.
   PubMed Web of Science ®Google Scholar
• Khan O, Fotheringham S, Wood V et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A. 2010;107(14):6532–6537.
   PubMed Web of Science ®Google Scholar
• Duvic M, Olsen EA, Breneman D, et al. Evaluation of the longterm tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2009;9(6):412–416.
   PubMedGoogle Scholar
• O’Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24(1):166–173.
   PubMed Web of Science ®Google Scholar
• Cheriyath V Kuhns MA, Kalaycio ME, Borden EC. Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br J Cancer. 2011;104(6):957–967.
   Web of Science ®Google Scholar
• Terpos E. The synergistic effect of panobinostat (LBH589) with mel- phalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients. Leuk Res. 2011;35(3):295–296.
   Web of Science ®Google Scholar
• Bellos F, Mahlknecht U. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie. 2008;31(11):629–633.
   PubMedGoogle Scholar
• Page P, Yang LX. Novel chemoradiosensitizers for cancer therapy. Anticancer Res. 2010;30(9):3675–3682.
   PubMed Web of Science ®Google Scholar
• Dummer R, Hymes K, Sterry W, et al. Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: A phase I study (abstract). J Clin Oncol. 2009;27(15s):8572.
   Google Scholar
• Steinhoff M, Beyer M, Roewert-Huber J, et al. Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. J Am Acad Dermatol. 2008;58(5 Suppl 1):S88–S91.
   Web of Science ®Google Scholar
• Gardner JM, Introcaso CE, Nasta SD, Kim EJ, Vittorio CC, Rook AH. A novel regimen of vorinostat with interferon gamma for refractory Sezary syndrome. J Am Acad Dermatol. 2009;61(1):112–116.
   PubMed Web of Science ®Google Scholar
• Sanli H, Akay BN, Anadolu R, Ozcan M, Saral S, Akyol A. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome. J Drugs Dermatol. 2011;10(4):403–408.
   Web of Science ®Google Scholar
• Heider U, Rademacher J, Lamottke B, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur J Haematol. 2009;82(6):440–449.
   PubMed Web of Science ®Google Scholar
• Zhang QL, Wang L, Zhang YW, et al. The proteasome inhibitor bort- ezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia. 2009;23(8):1507–1514.
   PubMed Web of Science ®Google Scholar
• Truee O, Matthias P. Interplay between histone deacetylases and autophagy – from cancer therapy to neurodegeneration. Immunol Cell Biol. 2011;29(10):103.
   Google Scholar
• Chen J, Fiskus W, Eaton K, et al. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood. 2009;113(17):4038–4048.
   Web of Science ®Google Scholar
• Wozniak MB, Villuendas R, Bischoff JR, et al. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica. 2010;95(4):613–621.
   PubMed Web of Science ®Google Scholar